ArcanaBio signs agreement with North Texas Genome Center, University of Texas Arlington

Apr 28, 2023

ArcanaBio secures 2nd grant from Sýklalyfjaónæmis- og súnusjóð to combat Antimicrobial Resistance

Apr 1, 2023

ArcanaBio's Rapid Saliva-Based COVID-19 Test Achieves 94.3% Sensitivity in Comparative Trial

Mar 15, 2022

ArcanaBio awarded 50m ISK grant from Technology Development Fund for Rapid Food pathogen tests

Mar 1, 2022

ArcanaBio awarded ISK 9m grant for rapid detection of Antimicrobial Resistance

Feb 28, 2021